C4 Therapeutics, Inc. CCCC
3.12 USD -0.09 (-2.80%)
At closeNov 5, 2026, 4:42 AM EST
2.81 -0.31 -9.94%
Pre-market · Nov 5, 4:42 AM ET
3.02 Day range 3.39
1.69 52-week range 5.17
- YTD
- +63.35%
- 1 year
- +31.65%
News
globenewswire.com C4 Therapeutics to Participate in Upcoming November Investor Conferences WATERTOWN, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD)…
globenewswire.com C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) WATERTOWN, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science,…
zacks.com C4 Therapeutics, Inc. (CCCC) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release C4 Therapeutics (CCCC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
globenewswire.com C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders WATERTOWN, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD)…
benzinga.com Lake Street Initiates Coverage On C4 Therapeutics with Buy Rating, Announces Price Target of $11 Lake Street analyst Chad Messer initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Buy rating and announces Price Target of $11.
benzinga.com JP Morgan Initiates Coverage On C4 Therapeutics with Overweight Rating, Announces Price Target of $10 JP Morgan analyst Anupam Rama initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Overweight rating and announces Price Target of $10.